Heparin-Binding Protein Refolding via Sulfated Polyanionic Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing heparin-binding proteins in bacterial cell cultures face challenges with protein misfolding and the presence of biologically inactive intermediates, leading to inefficient recovery of biologically active, properly refolded proteins.
Innovation Solution
A method involving the isolation of insoluble heparin-binding proteins from bacterial cells, solubilization in a chaotropic agent and reducing agent solution, followed by incubation in a second solution with a sulfated polyanionic agent to facilitate refolding, resulting in a 2 to 10-fold increase in biologically active protein concentration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If heparin-binding proteins are produced in bacterial cell cultures, then production cost is reduced and productivity is increased, but protein misfolding occurs and biologically inactive intermediates are formed
Solution Approach 1:
The patent segments the protein recovery process into distinct stages: isolation of insoluble protein, solubilization in chaotropic agent, and refolding in sulfated polyanionic agent solution. This segmentation allows each step to be optimized independently, addressing the folding issue without sacrificing productivity.
Solution Approach 2:
The patent introduces sulfated polyanionic agents as intermediary substances that mediate the refolding process. These agents act as molecular chaperones, facilitating correct protein folding and reducing misfolding intermediates while maintaining high productivity.
2Ease of manufacture
If traditional solubilization and refolding methods are used, then process simplicity is maintained, but recovery of biologically active protein is inefficient
Solution Approach 1:
The patent changes key chemical parameters by introducing sulfated polyanionic agents at specific concentrations (0.1-10 mg/mL) and pH conditions (pH 6-9). These parameter changes dramatically improve active protein recovery (2-10 fold increase) while maintaining reasonable process simplicity through straightforward incubation steps.
3Quantity of substance
If bacterial expression systems are used, then production cost decreases, but presence of biologically inactive intermediates increases
Solution Approach 1:
The patent converts the harmful effect of bacterial expression (producing misfolded intermediates) into a benefit by designing a refolding process that specifically targets and eliminates these intermediates. The sulfated polyanionic agents transform the problematic insoluble protein into correctly folded active protein, turning the bacterial system's weakness into a manageable step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively reduces biologically inactive intermediates and improves the recovery of highly purified, biologically active heparin-binding proteins, enhancing the efficiency of protein refolding and purification.
Implementation Method 1
solubilizing said isolated insoluble heparin binding protein in a first buffered solution comprising a chaotropic agent and a reducing agent
Implementation Method 2
solubilizing said isolated insoluble heparin binding protein in a first buffered solution comprising a chaotropic agent and a reducing agent
Implementation Method 3
incubating said solubilized heparin binding protein in a second buffered solution comprising a chaotropic agent and a sulfated polyanionic agent for such a time and under such conditions that refolding of the heparin binding protein occurs
Implementation Method 4
heparin affinity chromatography has been employed in various purification schemes
Data Source
AI summary
A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.